IXICO to Receive £2.1M from Biomedical Catalyst

IXICO, a London, UK-based medical imaging company, will receive £2.1m from the government-backed Biomedical Catalyst.

The company intends to use the funding to accelerate the translation of scientific ideas into commercial propositions.
It will lead a project to develop a novel digital healthcare platform which provides earlier and more accurate diagnosis of dementia by opening up advanced investigative techniques usually only available in specialist centres to doctors diagnosing all patients. Computer-based tests of memory and thinking will be combined with computerized analysis of MRI brain scans to yield automated and accurate diagnostic reports that lead to rapid treatment and support for people with dementia and their carers. The three-year collaborative project aims to demonstrate that time to diagnosis of dementia can be reduced by 15 months and bring diagnosis rates closer to the Prime Minister’s Dementia Challenge target rate of 80%.
The company will work alongside Cambridge Cognition, a UK developer of neuropsychological tests, and their project partners at King’s College London, University of Sussex and Imperial College London.

Led by Derek Hill, CEO, IXICO is a medical imaging company that provides software solutions and services to deliver imaging biomarkers in clinical trials, research studies and health care diagnostics. It is backed by Imperial Innovations Group plc (AIM: IVO).

Biomedical Catalyst is a £180m funding programme for businesses and academics in the life sciences sector which is managed jointly by the Technology Strategy Board and the Medical Research Council.



Join the discussion